Your browser doesn't support javascript.
A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection.
Beaudoin-Bussières, Guillaume; Chen, Yaozong; Ullah, Irfan; Prévost, Jérémie; Tolbert, William D; Symmes, Kelly; Ding, Shilei; Benlarbi, Mehdi; Gong, Shang Yu; Tauzin, Alexandra; Gasser, Romain; Chatterjee, Debashree; Vézina, Dani; Goyette, Guillaume; Richard, Jonathan; Zhou, Fei; Stamatatos, Leonidas; McGuire, Andrew T; Charest, Hughes; Roger, Michel; Pozharski, Edwin; Kumar, Priti; Mothes, Walther; Uchil, Pradeep D; Pazgier, Marzena; Finzi, Andrés.
  • Beaudoin-Bussières G; Centre de recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Chen Y; Infectious Disease Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4712, USA.
  • Ullah I; Department of Internal Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT 06520, USA.
  • Prévost J; Centre de recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Tolbert WD; Infectious Disease Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4712, USA.
  • Symmes K; Department of Internal Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT 06520, USA.
  • Ding S; Centre de recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Benlarbi M; Centre de recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Gong SY; Centre de recherche du CHUM, Montreal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada.
  • Tauzin A; Centre de recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Gasser R; Centre de recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Chatterjee D; Centre de recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Vézina D; Centre de recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Goyette G; Centre de recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Richard J; Centre de recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Zhou F; Division of Basic and Translational Biophysics, Unit on Structural Biology, NICHD, NIH, Bethesda, MD 20892, USA.
  • Stamatatos L; Vaccine and Infectious Disease Division, Fred Hutchinson Center, Seattle, WA 98195, USA; Department of Global Health, University of Washington, Seattle, WA 98195, USA.
  • McGuire AT; Vaccine and Infectious Disease Division, Fred Hutchinson Center, Seattle, WA 98195, USA; Department of Global Health, University of Washington, Seattle, WA 98195, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
  • Charest H; Laboratoire de Santé Publique du Québec, Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada.
  • Roger M; Centre de recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada; Laboratoire de Santé Publique du Québec, Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Ca
  • Pozharski E; University of Maryland Institute for Bioscience and Biotechnology Research, Rockville, MD 20850, USA; Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
  • Kumar P; Department of Internal Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT 06520, USA.
  • Mothes W; Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT 06510, USA.
  • Uchil PD; Department of Microbial Pathogenesis, Yale University School of Medicine, New Haven, CT 06510, USA. Electronic address: pradeep.uchil@yale.edu.
  • Pazgier M; Infectious Disease Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814-4712, USA. Electronic address: marzena.pazgier@usuhs.edu.
  • Finzi A; Centre de recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada. Electronic address: andres.finzi@um
Cell Rep ; 38(7): 110368, 2022 02 15.
Article in English | MEDLINE | ID: covidwho-1649284
ABSTRACT
Emerging evidence indicates that both neutralizing and Fc-mediated effector functions of antibodies contribute to protection against SARS-CoV-2. It is unclear whether Fc-effector functions alone can protect against SARS-CoV-2. Here, we isolated CV3-13, a non-neutralizing antibody, from a convalescent individual with potent Fc-mediated effector functions. The cryoelectron microscopy structure of CV3-13 in complex with the SARS-CoV-2 spike reveals that the antibody binds from a distinct angle of approach to an N-terminal domain (NTD) epitope that only partially overlaps with the NTD supersite recognized by neutralizing antibodies. CV3-13 does not alter the replication dynamics of SARS-CoV-2 in K18-hACE2 mice, but its Fc-enhanced version significantly delays virus spread, neuroinvasion, and death in prophylactic settings. Interestingly, the combination of Fc-enhanced non-neutralizing CV3-13 with Fc-compromised neutralizing CV3-25 completely protects mice from lethal SARS-CoV-2 infection. Altogether, our data demonstrate that efficient Fc-mediated effector functions can potently contribute to the in vivo efficacy of anti-SARS-CoV-2 antibodies.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 / Antibodies, Viral Type of study: Prognostic study Limits: Animals / Humans Language: English Journal: Cell Rep Year: 2022 Document Type: Article Affiliation country: J.celrep.2022.110368

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 / Antibodies, Viral Type of study: Prognostic study Limits: Animals / Humans Language: English Journal: Cell Rep Year: 2022 Document Type: Article Affiliation country: J.celrep.2022.110368